162
Views
0
CrossRef citations to date
0
Altmetric
LETTER

Comments on “Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project” [Letter]

, , ORCID Icon & ORCID Icon
Pages 431-432 | Received 08 Jun 2024, Accepted 12 Jun 2024, Published online: 13 Jun 2024

References

  • Spini A, L’Abbate L, Ingrasciotta Y, et al. Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: insights from the VALORE Project. Clin Epidemiol. 2024;16:395–407. doi:10.2147/CLEP.S445120
  • Ingrasciotta Y, Spini A, L’Abbate L, et al. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: an external validity analysis of 66,639 biologic users from the Italian VALORE project. Pharmacol Res. 2024;200:107074. doi:10.1016/j.phrs.2024.107074
  • Monteleone G, Moscardelli A, Colella A, Marafini I, Salvatori S. Immune-mediated inflammatory diseases: common and different pathogenic and clinical features. Autoimmune Rev. 2023;22(10):103410. doi:10.1016/j.autrev.2023.103410
  • Jourdain H, Hoisnard L, Sbidian E, Zureik M. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System. RMD Open. 2024;10(1):e003531. doi:10.1136/rmdopen-2023-003531